Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $2.5 million.

  • Lineage Cell Therapeutics' Accumulated Expenses rose 200.48% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 200.48%. This contributed to the annual value of $3.1 million for FY2024, which is 182.52% down from last year.
  • Lineage Cell Therapeutics' Accumulated Expenses amounted to $2.5 million in Q3 2025, which was up 200.48% from $2.2 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Accumulated Expenses' 5-year high stood at $22.1 million during Q4 2021, with a 5-year trough of $1.2 million in Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.5 million (2024), whereas its average is $5.4 million.
  • In the last 5 years, Lineage Cell Therapeutics' Accumulated Expenses soared by 158539.33% in 2022 and then crashed by 9138.1% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Accumulated Expenses (Quarter) stood at $22.1 million in 2021, then crashed by 82.65% to $3.8 million in 2022, then decreased by 18.52% to $3.1 million in 2023, then decreased by 1.83% to $3.1 million in 2024, then fell by 17.03% to $2.5 million in 2025.
  • Its Accumulated Expenses stands at $2.5 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.1 million for Q1 2025.